Abstract
Background: Amyloid beta (Aβ) accumulates in the human brain in an age-dependent manner during normal aging. However, Aβ accumulation has not been observed in rodents during normal aging. Tree shrews, the experimental animals studied here, are as small as rats but have a longer life span than rodents.
Methods: We investigated Aβ accumulations in the brains of young and aged tree shrews by amyloid histochemistry and immunohistochemistry using antibodies to Aβ-42, Aβ-40, Aβ-16 and amyloid precursor protein (APP).
Results: In the brain of young tree shrews, there were no Aβ- immunoreactive (-ir) and APP-ir profiles. In the brains of aged tree shrews, Aβ-42-ir neuronal profiles were observed in the cortex, subiculum, basal ganglia, mammillary body and hypothalamus, but there were only a few weak Congo red-positive amyloid deposits. Aβ-42-, Aβ-40-, Aβ-16- and APP-ir blood vessels were observed.
Conclusions: An early stage of amyloid accumulation occurs in the brains of aged tree shrews, indicating that this animal may be a good model for studying the start of Aβ accumulation.
Keywords: Normal aging, blood vessel, amyloid deposit, Congo red, Alzheimer’s disease, Tupai belangeri.
Current Aging Science
Title: Amyloid Beta (Aβ) Protein- and Amyloid Precursor Protein (APP)- Immunoreactive Structures in the Brains of Aged Tree Shrews
Volume: 3 Issue: 3
Author(s): Akiko Yamashita, Eberhard Fuchs, Masato Taira and Motoharu Hayashi
Affiliation:
Keywords: Normal aging, blood vessel, amyloid deposit, Congo red, Alzheimer’s disease, Tupai belangeri.
Abstract: Background: Amyloid beta (Aβ) accumulates in the human brain in an age-dependent manner during normal aging. However, Aβ accumulation has not been observed in rodents during normal aging. Tree shrews, the experimental animals studied here, are as small as rats but have a longer life span than rodents.
Methods: We investigated Aβ accumulations in the brains of young and aged tree shrews by amyloid histochemistry and immunohistochemistry using antibodies to Aβ-42, Aβ-40, Aβ-16 and amyloid precursor protein (APP).
Results: In the brain of young tree shrews, there were no Aβ- immunoreactive (-ir) and APP-ir profiles. In the brains of aged tree shrews, Aβ-42-ir neuronal profiles were observed in the cortex, subiculum, basal ganglia, mammillary body and hypothalamus, but there were only a few weak Congo red-positive amyloid deposits. Aβ-42-, Aβ-40-, Aβ-16- and APP-ir blood vessels were observed.
Conclusions: An early stage of amyloid accumulation occurs in the brains of aged tree shrews, indicating that this animal may be a good model for studying the start of Aβ accumulation.
Export Options
About this article
Cite this article as:
Yamashita Akiko, Fuchs Eberhard, Taira Masato and Hayashi Motoharu, Amyloid Beta (Aβ) Protein- and Amyloid Precursor Protein (APP)- Immunoreactive Structures in the Brains of Aged Tree Shrews, Current Aging Science 2010; 3 (3) . https://dx.doi.org/10.2174/1874609811003030230
DOI https://dx.doi.org/10.2174/1874609811003030230 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aquaporin and Vascular Diseases
Current Neuropharmacology Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets Targeting Carcinogen Metabolism by Dietary Cancer Preventive Compounds
Current Cancer Drug Targets Protein kinases and the Hypoxia-Inducible Factor-1, two switches in angiogenesis
Current Pharmaceutical Design Short Peptide Modules for Enhancing Intestinal Barrier Function
Current Pharmaceutical Design Prostate Cancer Horizons in the Development of Novel Anti-Cancer Strategies
Current Medicinal Chemistry - Anti-Cancer Agents The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors
Current Drug Metabolism The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry Pharmacogenetics of Oxazaphosphorines and its Clinical Implications
Current Pharmacogenomics Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Pim Kinases: New Targets for Drug Development
Current Drug Targets T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Stereological Quantification of Blood and Lymph Microvessels in Prostate Cancer. Its Relevance for the Anti-angiogenetic Therapy
Current Cancer Therapy Reviews A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Adeno-associated Viral Vectors for Correction of Inborn Errors of Metabolism: Progressing Towards Clinical Application
Current Pharmaceutical Design Heparanase Inhibitors Facilitate the Assembly of the Basement Membrane in Artificial Skin
Current Tissue Engineering (Discontinued)